[go: up one dir, main page]

WO2016034715A3 - Methode de prediction de l'evolution clinique du cancer colorectal - Google Patents

Methode de prediction de l'evolution clinique du cancer colorectal Download PDF

Info

Publication number
WO2016034715A3
WO2016034715A3 PCT/EP2015/070268 EP2015070268W WO2016034715A3 WO 2016034715 A3 WO2016034715 A3 WO 2016034715A3 EP 2015070268 W EP2015070268 W EP 2015070268W WO 2016034715 A3 WO2016034715 A3 WO 2016034715A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
stage
colorectal cancer
methods
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/070268
Other languages
English (en)
Other versions
WO2016034715A2 (fr
Inventor
Laurent TOSOLINI
Gilles VIEIRA
Alexandre Ho-Pun-Cheung
Caroline MOLLEVI
Evelyne Crapez
Eric ASSENAT
Odile PRIGNEAU
Guillaume VETTER-GENOUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRESTIZIA
Institut Regional du Cancer de Montpellier
Original Assignee
PRESTIZIA
Institut Regional du Cancer de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRESTIZIA, Institut Regional du Cancer de Montpellier filed Critical PRESTIZIA
Publication of WO2016034715A2 publication Critical patent/WO2016034715A2/fr
Publication of WO2016034715A3 publication Critical patent/WO2016034715A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente demande concerne des compositions et méthodes pour analyser et caractériser des patients atteints de cancer colorectal, et plus particulièrement ceux atteints de cancer du rectum localement avancé de stade II et III. Elle concerne notamment des méthodes et réactifs (amorces, puces, DNA chips, sondes, NGS, real-time PCR etc.) pour déterminer ou évaluer l'évolution clinique de tels cancers, et plus particulièrement pour apprécier leur caractère répondeur au traitement RCT et/ou pour déterminer le risque de récidive métastatique chez ces patients. L'invention repose notamment sur la détection de miRNAs circulants. Elle est utilisable chez tout patient, et tout particulièrement chez les patients ayant un cancer de stade II ou III.
PCT/EP2015/070268 2014-09-05 2015-09-04 Methode de prediction de l'evolution clinique du cancer colorectal Ceased WO2016034715A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14183831.8 2014-09-05
EP14183831 2014-09-05

Publications (2)

Publication Number Publication Date
WO2016034715A2 WO2016034715A2 (fr) 2016-03-10
WO2016034715A3 true WO2016034715A3 (fr) 2016-06-02

Family

ID=51518569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/070268 Ceased WO2016034715A2 (fr) 2014-09-05 2015-09-04 Methode de prediction de l'evolution clinique du cancer colorectal

Country Status (1)

Country Link
WO (1) WO2016034715A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106119347A (zh) * 2016-06-24 2016-11-16 山东大学齐鲁医院 基于血清exosomal microRNAs的结直肠癌转移检测的引物和试剂盒
CN107130017B (zh) * 2017-03-31 2021-01-15 北京大学人民医院 试剂盒及试剂在制备试剂盒中的用途
CN109385472B (zh) * 2018-12-07 2021-10-08 中国科学院近代物理研究所 一种血清miRNA标志物及其检测电离辐射损伤的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115609A1 (fr) * 2015-01-20 2016-07-28 Katholieke Universiteit Leuven Cancer du côlon
CN106367477A (zh) * 2016-08-25 2017-02-01 朱伟 一种与结直肠癌辅助诊断相关的血清miRNA标志物及其应用
CN107974501A (zh) * 2016-10-19 2018-05-01 北京旷博生物技术股份有限公司 结直肠癌预后microRNA分子标志物及其用途
CN117683885A (zh) * 2019-04-30 2024-03-12 觅瑞实验室私人有限公司 一种检测胃癌的miRNA标志物组合及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111643A2 (fr) * 2008-03-06 2009-09-11 Asuragen, Inc. Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2010004562A2 (fr) * 2008-07-09 2010-01-14 Rosetta Genomics Ltd. Procédés et compositions permettant de détecter un cancer colorectal
WO2013093635A2 (fr) * 2011-10-21 2013-06-27 Hospital Clinic De Barcelona Microarn du plasma pour la détection du cancer colorectal précoce

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111643A2 (fr) * 2008-03-06 2009-09-11 Asuragen, Inc. Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2010004562A2 (fr) * 2008-07-09 2010-01-14 Rosetta Genomics Ltd. Procédés et compositions permettant de détecter un cancer colorectal
WO2013093635A2 (fr) * 2011-10-21 2013-06-27 Hospital Clinic De Barcelona Microarn du plasma pour la détection du cancer colorectal précoce

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Arraystar Handbook miRStar(TM) PCR Array Systems", 3 July 2014 (2014-07-03), XP055169727, Retrieved from the Internet <URL:http://web.archive.org/web/20150213151200/http://www.arraystar.com/Manage/UploadFile/Handbook/Arraystar Handbook-miRStar PCR Array Systems.pdf> [retrieved on 20150213] *
ELRASHEID A. H. KHEIRELSEID ET AL: "miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol. 28, no. 2, 18 August 2012 (2012-08-18), DE, pages 247 - 260, XP055230598, ISSN: 0179-1958, DOI: 10.1007/s00384-012-1549-9 *
I-PING YANG ET AL: "The Functional Significance of MicroRNA-29c in Patients with Colorectal Cancer: A Potential Circulating Biomarker for Predicting Early Relapse", PLOS ONE, vol. 8, no. 6, 28 June 2013 (2013-06-28), pages e66842, XP055169156, DOI: 10.1371/journal.pone.0066842 *
QI CHEN ET AL: "Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases", ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol. 14, no. 12, 31 December 2013 (2013-12-31), pages 7421 - 7426, XP055169307, ISSN: 1513-7368, DOI: 10.7314/APJCP.2013.14.12.7421 *
TOIYAMA YUJI ET AL: "Serum miR-200c is a novel prognostic and metastasis-predictive biomarkerin patients with colorectal cancer", ANNALS OF SURGERY, vol. 259, no. 4, April 2014 (2014-04-01), United States, pages 735 - 743, XP008174889 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106119347A (zh) * 2016-06-24 2016-11-16 山东大学齐鲁医院 基于血清exosomal microRNAs的结直肠癌转移检测的引物和试剂盒
CN106119347B (zh) * 2016-06-24 2019-12-03 山东大学齐鲁医院 基于血清exosomal microRNAs的结直肠癌转移检测的引物和试剂盒
CN107130017B (zh) * 2017-03-31 2021-01-15 北京大学人民医院 试剂盒及试剂在制备试剂盒中的用途
CN109385472B (zh) * 2018-12-07 2021-10-08 中国科学院近代物理研究所 一种血清miRNA标志物及其检测电离辐射损伤的方法

Also Published As

Publication number Publication date
WO2016034715A2 (fr) 2016-03-10

Similar Documents

Publication Publication Date Title
WO2016034715A3 (fr) Methode de prediction de l&#39;evolution clinique du cancer colorectal
Liloglou et al. Epigenetic biomarkers in lung cancer
MX375586B (es) Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo.
HK1255533A1 (zh) 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板
HK1246828A1 (zh) 用於检测癌症的生物标志物组
EP3640341A3 (fr) Analyses pour déterminer la méthylation de l&#39;adn et marqueurs de méthylation de l&#39;adn du cancer
SG11201805531UA (en) Molecular detection/diagnosis reagent for tumor
WO2014140933A3 (fr) Procédé de pronostic et de traitement de métastases cancéreuses
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
HK1219763A1 (zh) 用於癌症预後的组合物和方法
WO2015172085A3 (fr) Biomarqueurs utilisables pour évaluer la réponse aux inhibiteurs de la pi3k
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
EP4246144A3 (fr) Compositions et méthodes de recherche de mutations dans le cancer de la thyroïde
MA39951A (fr) Détection de l&#39;adn provenant d&#39;un type spécifique de cellule et méthodes associées
WO2016109782A3 (fr) Méthodes et compositions pour la détection de néoplasies colorectales
EP4484572A3 (fr) Identification et utilisation de marqueurs tumoraux d&#39;acides nucléiques circulants
MX2017015210A (es) Composiciones y metodos para el cribado de tumores solidos.
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
NZ629538A (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
EP3572529A3 (fr) Diagnostic du cancer colorectal basé sur la méthylation de gènes
MX376755B (es) Detección de ácidos nucleicos diana mediante el uso de hibridación.
WO2015153732A3 (fr) Utilisation d&#39;adn double brin dans des exosomes : un nouveau biomarqueur dans la détection du cancer
WO2016198833A3 (fr) Procédés
WO2019094780A3 (fr) Arn non codant pour la détection du cancer
WO2017042625A3 (fr) Sous-typage moléculaire, pronostic et traitement du cancer de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15759459

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15759459

Country of ref document: EP

Kind code of ref document: A2